Germany· DE-A57-6c6f68f423e1d1ff
Metopiron
A metyrapone product containing metyrapone, registered in Germany by Esteve Rd France S.A.S.. The same ATC class is registered in 14 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Metyrapone is registered in 14 of 19 countries.
Countries holding a registration under ATC V04CD01 (metyrapone), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 8 of them publish a price we can compare per daily dose
Metyrapone · ATC V04CD01
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of metyrapone costs, country by country.
Normalised to the WHO defined daily dose (3 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Metyrapone · price per daily dose (3 g)
USD · FX 28 Sept 2026
- CH Switzerland$91.87
- FR France$70.58
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Metyrapone
- Manufacturer
- Esteve Rd France S.A.S.
- Country
- Germany (DE)
- ATC code
- V04CD01
- ATC class
- Metyrapone
- Defined daily dose
- 3 g, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
14 interactions on record for metyrapone.
Graded by severity as the source publishes them — 14 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Metyrapone · interactions on record
14 records
- 14 moderate
Most severe, free to view
- CyproheptadinA15AA01moderate
- EstradiolD11AX34moderate
- Levonorgestrel and ethinylestradiolG03AA07moderate
- Desogestrel and ethinylestradiolG03AA09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under V04CD01
Metyrapone, as other registers publish it.
- GermanyMetopironEsteve Pharmaceuticals, S.A.
- FinlandMetopironNovartis Pharma Stein AG
- GermanyMetopironHra Pharma Rare Diseases
- SwitzerlandMetopiron, KapselnEffRx Pharmaceuticals SA
- SwitzerlandMetopiron, KapselnEffRx Pharmaceuticals SA
- PolandMetopironeEsteve Pharmaceuticals, S.A.
- FinlandMetopironeEsteve Pharmaceuticals S.A.S.
- United StatesMetopironeHRA Pharma Rare Diseases
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fd7b5df0-22d6-4121-91a8-a9faa56ddc20 GET /v1/drugs/fd7b5df0-22d6-4121-91a8-a9faa56ddc20?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Metyrapone",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about metyrapone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.